Distinguishing adrenal cortical adenomas from carcinomas may be a difficult diagnostic problem. The criteria of Weiss are very useful because of their reliance on histologic features. From a practical perspective, the most useful criteria to separate adenomas from carcinomas include tumor size, presence of necrosis and mitotic activity including atypical mitoses. Adrenal cortical neoplasms in pediatric patients are more difficult to diagnose and to separate adenomas from carcinomas. The diagnosis of pediatric adrenal cortical carcinoma requires a higher tumor weight, larger tumor size and more mitoses compared with carcinomas in adults. Pheochromocytomas are chromaffin-derived tumors that develop in the adrenal gland. Paragangliomas are tumors arising from paraganglia that are distributed along the parasympathetic nerves and sympathetic chain. Positive staining for chromogranin and synaptophysin is present in the chief cells, whereas the sustentacular cells are positive for S100 protein. Hereditary conditions associated with pheochromocytomas include multiple endocrine neoplasia 2A and 2B, Von Hippel-Lindau disease and neurofibromatosis I. Hereditary paraganglioma syndromes with mutations of SDHB, SDHC and SDHD are associated with paragangliomas and some pheochromocytomas.
The normal adrenal contains three zones in the cortex (glomerulosa, fasciculata and reticularis), whereas the adrenal medulla is located in the central portion of the gland.
Adrenal cortical adenomas ( Figure 1a ) commonly arise from the zona fasciculata, although all three zones can give rise to benign or malignant tumors. Adrenal cortical adenomas may be functioning or nonfunctioning. 1 These tumors are usually positive for melan A by immunostaining (Figure 1b) . 1 Many small adenomas o3 cm in diameter are discovered accidentally during working up for various other conditions. These tumors are referred to as 'incidentalomas'. One of the major problems in diagnostic endocrine pathology is distinguishing adrenal cortical adenomas from carcinomas. This is especially true with borderline lesions compared with small adenomas o20 g or very large tumors 4500 g that are usually obvious carcinomas.
Adrenal cortical carcinoma may be functioning malignancies in some cases, whereas in other cases they are nonfunctioning. [1] [2] [3] [4] [5] [6] The gross appearance of adrenal cortical carcinoma can be very helpful in making the diagnosis. Most carcinomas in adults are 4100 g, whereas adenomas generally weigh 50 g or less. Adrenal cortical tumors weighing o50 g have, on occasion, metastasized, but this is extremely uncommon. In pediatric patients, however, adrenal cortical adenomas may weigh up to 500 g. In addition to tumor weight, the presence of necrosis usually indicates an adrenal cortical carcinoma unless the necrosis resulted from a traumatic insult such as FNA. A variegated appearance with nodularity and intersecting fibrous bands should also suggest the possibility of a carcinoma.
Various studies have outlined specific criteria used to diagnose adrenal cortical carcinomas. [7] [8] [9] [10] The criteria of Weiss 8, 9 are most useful because of their reliance on histologic features. These include high nuclear grade, mitotic rate 45 per 50 HPF, atypical mitotic figures, eosinophilic tumor cells (Z75% of tumor), diffuse architecture (Z33% of tumor), necrosis, venous invasion (smooth muscle in wall), sinusoidal invasion (no smooth muscle in wall) and capsular invasion 8, 9 ( Figure 2a and b) . Three or more of the nine criteria are indicative of an adrenal cortical carcinoma, whereas two or less would be more in keeping with an adenoma. The modification of the Weiss system by Aubert et al 10 has somewhat simplified the Weiss criteria. Other systems such as that of van Slooten et al 11 attach numeric values to the various criteria, and an index of eight or higher was consistent with a carcinoma.
One of the older systems is that of Hough et al, 12 who used histologic criteria and clinical parameters in their assessment of adrenal cortical neoplasms. A numeric value of 2.91 was indicative of malignancy, whereas a value of 0.17 or less was consistent with a benign lesion. The disadvantage of this system is the reliance on clinical parameters as well as histologic features, and some of these clinical parameters, may not be available when examining the specimen. From a practical perspective, the most useful criteria to separate adenomas from carcinomas include tumor size, presence of necrosis, mitotic activity including atypical mitoses, invasive growth and high nuclear grade. Capsular invasion may be difficult to recognize because the expanding capsule may be a preexisting adrenal capsule. Invasion of adjacent soft tissue, kidney or liver is definitive sign of malignancy. Special studies may be useful in confirming the nature of the malignant tissue. [13] [14] [15] [16] [17] [18] [19] Ultrastructural studies may show the distinct features of ACC tissues including abundant smooth endoplasmic reticulum and mitochondria with prominent tubular or vesicular cristae. Immunohistochemical studies that are most useful in adrenal cortical carcinoma include melan A, inhibin-a and calretinin. Stains for cytokeratin are usually weakly positive, whereas vimentin is strongly positive. Synaptophysin is usually weakly positive in these tumors. Chromogranin is consistently negative. A marker for adrenal cortical cells, Ad4BP/SP-1, is relatively restricted in its distribution 20, 21 and may be useful in the diagnosis of adrenal cortical tissues. This protein is a transcription factor that is needed for embryonic development of adrenal cortical cells. Adrenal cortical neoplasm in pediatric patients is more difficult to diagnose and to separate adenomas from carcinomas. 22 In a study of 83 adrenal cortical neoplasms, only 31% of histologically malignant tumors behaved in a clinically malignant manner. Features of malignancy included tumor weight 4400 g, tumor size 410.5 cm, vena cava invasion, confluent necrosis, periadrenal soft tissue invasion 415 mitoses per HPF and atypical mitoses.
There are several variants of adrenal cortical tumors. The most common include the oncocytic tumors, 23, 24 and the myxoid variant. 25 Criteria for the diagnosis of oncocytic carcinomas were recently proposed by Weiss' group. 24 Major criteria for oncocytic tumors included high mitotic rate, atypical mitoses and vena cava invasion. Minor criteria included large size and weight, necrosis, capsular invasion and sinusoidal invasion. One major criterion indicated malignancy, whereas 1-4 minor criteria indicated borderline tumors. Absence of all major and minor criteria indicated benign oncocytic tumors. The myxoid variant of adrenal cortical tumors looks different morphologically, but the criteria for malignancy should be similar to conventional adrenal cortical tumors.
The differential diagnosis of adrenal cortical carcinoma includes renal cell carcinoma, hepatocellular carcinoma, pheochromocytomas, and metastatic carcinomas and melanomas. Insulin-like growth factor-2 has been useful in the classification of adrenal cortical tumors. 26 Recent studies of these various markers and techniques separate adrenal cortical carcinomas from adenomas. Some of these include DNA flow cytometric analysis and nucleolar organizer regions have not been very effective. However, some markers of proliferation have been shown to be useful in the distinction. Ki-67 labeling index with MIB-1 antibody are somewhat promising. 19, 20 Molecular Studies Molecular studies have characterized various genes that are differentially expressed in normal and benign compared with malignant adrenal cortical tumors. [27] [28] [29] [30] [31] The phenotypes of Ki-67-negative, p53-negative, mdm-2-positive, cyclin-D1-negative, Bcl-2-negative, p21-negative and p27-positive cells were found in 83% of normal adrenal tissues, but only in 3% of malignant tumors. 27 Giordano and colleagues 28, 29 performed microarray analysis of adrenal cortical tumors and reported upregulation of IGF2 in 10% of adrenal cortical carcinomas (90.9%). Proliferation in related genes such as TOP2A and Ki-67 was also upregulated in carcinomas. VelazquezFernandez et al 30 performed expression profiling of 7 patients with adrenal cortical carcinomas and 13 with adenomas and reported upregulation of ubiquitin-related genes (USP4 and UFD1L) and insulinlike growth factor-related genes (IGF2, IGF2R, IGFbP3 and IGFbP6). A cytokine gene (CXCL10) and cadherin 2 gene (CDH2) were downregulated in carcinomas compared with adenomas. 30 
Pheochromocytomas and paragangliomas
Pheochromocytomas ('dusky colored tumor') are chromaffin-derived tumors that develop in the adrenal gland.
1 When the tumor is immersed in chromaffin salts or other weak oxidizing agents, it develops the dusky color. Most tumors are sporadic and benign. The reported incidence is about 0.4-9.5 per 10 6 people. The tumors occur most frequently in the fourth and fifth decades. Familial tumors develop at a younger age. Most familial tumors are bilateral, whereas sporadic tumors are unilateral.
Patients usually present with throbbing headaches, sweating, palpitations, chest and abdominal pains. The 'spells' may last from 10 to 60 min and may be triggered by positional changes.
Pheochromocytomas usually form cell nests composed of cells with abundant basophilic cytoplasm (Figure 3a) . Ultrastructural features include dense core secretory granules (Figure 3b) .
Malignant pheochromocytomas comprise only about 10% of all pheochromocytomas. Signs and symptoms are similar to these in patients with benign disease; however, catecholamine production and the degree of hypertension may be more marked with metastatic disease.
Imaging studies cannot distinguish benign from malignant pheochromocytomas unless there is metastatic disease. CT studies and iodine-123-metaiodobenzyl-guanidine is very useful in imaging especially for locally recurrent or metastatic disease.
Malignant pheochromocytomas tend to be larger tumors than benign ones. They may be more nodular, lobular and show areas of necrosis. They may infiltrate periadrenal adipose tissue. Metastatic disease is the most reliable evidence of malignancy. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] Histologic features suggesting malignancy include capsular invasion, vascular invasion, extension into periadrenal adipose tissue, diffuse growth, necrosis, tumor cell spindling, increased cellularity, marked nuclear pleomorphism, macronucleoli, increased mitoses including atypical mitoses, absence or decreased hyaline globules. Sustentacular cells were reported to be decreased or absent in malignant pheochromocytomas.
1 MIB-1 labeling index may be helpful in separating benign and malignant pheochromocytomas. However, in some larger studies using 2.5 or 3.0% of cutoff points had a sensitivity of only 50% in identifying proven malignant tumors.
The Pheochromocytomas of the Adrenal Gland Scaled Score (PASS) was developed by Thompson to distinguish benign from malignant pheochromocytomas. 46 It uses features such as growth pattern, necrosis, cellularity, cellular monotony, tumor cell spindling, mitotic count, atypical mitosis, invasion, nuclear pleomorphism and hyperchromasia to try to separate tumors. A PASS of Z4 is associated with a higher probability for malignancy. The use of the PASS was not validated independently in a recent study by a group of endocrine pathologists. 47 Other studies of malignant pheochromocytomas have been recently reported. 34, [48] [49] [50] The proposed system of Kimura et al 34 used an assigned score that adds up to a maximum of 10 Ki-67 immunoreactivity along with catecholamine and phenotype. With a score of 7-10, 100% of patients were found to have malignant tumors.
34
Paragangliomas (PGLs) are tumors arising from the paraganglia that are distributed along the parasympathetic nerves in the head, neck and mediastinum, and along the sympathetic chain such as the cervical, intrathoracic, supraneural inferior paraaortic and urinary bladder. Although morphologic distinction between pheochromocytomas and PGLs is difficult, molecular differences between tumors arising in the adrenal medulla and other sites are more evident. As to malignancy, the general impression is that tumors arising in the organs of Zuckerkandl close to the bifurcation of the aorta have the highest incidence of malignancy.
Histopathologic features of pheochromocytomas and PGLs include chief cells with basophilic to amphophilic cells with abundant cytoplasm and large vesicular nuclei (Figure 4a 
Molecular Genetics
Pheochromocytomas associated with a variety of inherited conditions including multiple endocrine neoplasia type 2 (MEN2), Von Hippel-Lindau (VHL) disease, neurofibromatous type 1 (NF1), heredity PGL syndromes and Sturge-Weber disease. The genetics of these disorders are summarized in Table 1 . 51 Multiple endocrine neoplasia type 2 Approximately 50% of patients with MEN2 develop pheochromocytomas. De novo germ-line mutations occur in about 6% of MEN2A and familial medullary thyroid carcinoma cases and in around 50% of MEN2B cases.
Von Hippel-Lindau disease
The frequency of pheochromocytomas in VHL patients ranges from 10 to 30% and is restricted to the type 2 kindreds. Type 1 VHL patients with renal cell carcinomas, hemangioblastomas and retinal angiomas do not usually develop pheochromocytomas.
Neurofibromatosis type 1
Pheochromocytomas are associated with 1-4% of NF1 patients. NF1 carries 100% disease penetrance within families. The prevalence of pheochromocytomas in NF1 patients is greater than that in the general population. 
Hereditary paraganglioma syndromes
The frequency of succinate dehydrogenase B (SDHB) and SDHD mutations in pheochromocytomas is about 3-5%. These mutations are much more common in paragangliomas or extra-adrenal pheochromocytomas. SDHB mutations have been associated with malignant paragangliomas (Table 1) . Paragangliomas in the retroperitoneum are more likely to have SDHB mutations, and these are more commonly associated with malignancy. SDHC mutations are more common in head and neck paragangliomas that are usually benign. 52 The most recently described SDH mutation is SDHAF2. 52 The gene responsible for this mutation (PGL2) was initially termel SDHS. 52 The distribution of genetic abnormalities between familial and sporadic pheochromocytomas and paragangliomas is also strikingly different. 51 Recent studies have shown that immunohistochemical screening can be used to detect germ-line mutations of SDHB, SDHC and SDHD 53 with the use of the antibodies reported by this group. DHAF2 mutations are associated with tumors of the head and neck region. 1 The sporadic tumors stain positively, whereas tumors with germ-line mutations are negative (Figure 5a and b) . Molecular sequencing should be performed to validate the immunohistochemical findings. 53 
Prognosis
The usual prognosis of malignant pheochromocytomas is about 50%/5-year survival. Some patients may have indolent disease with a life expectancy of more than 20 years.
Molecular markers
A series of molecular markers have been reported as markers of malignancy in pheochromocytomas. 38 These include heat shock protein 9.0, human telomerase reverse transcriptase, vascular endothelial growth factor, vascular endothelial growth factor receptor hypoxia inducible factor 2-a, cyclooxygenase 2, tenascin C, N cadherin-and secretogranin IIderived peptide EM66. The practical application of these markups will require more studies.
Conclusions
The Weiss criteria are commonly used to separate adrenal cortical adenomas from carcinomas. Adrenal cortical neoplasms in pediatric patients are more difficult to diagnose and it is more difficult to separate benign from malignant tumors in this age group. Oncocytic and myxoid variants of adrenal cortical tumors are uncommon. Different criteria are used to diagnose oncocytic adrenal cortical carcinomas. Pheochromocytomas and paragangliomas are usually positive for chromogranin and synaptophysin, whereas the sustentacular cells in both tumor groups are positive for S100 protein. A careful family history and molecular analyses are helpful in the workup and diagnosis of familial pheochromocytomas and paragangliomas. Mutations of the SDH gene family are associated with hereditary paraganglioma syndrome and SDHB mutations, which occur more commonly in retroperitoneal paragangliomas, are frequently associated with malignant tumors.
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